IDO1 and cancer: In a recent review of IDO pathway inhibitors [43], the authors conclude that IDO-inhibition has been well tolerated in cancer patients, with clinical anticancer effects seen in a subset of patients, and that combination therapy with chemotherapy, radiotherapy or immunotherapy may be effective against a wide range of malignancies.